This company has been marked as potentially delisted and may not be actively trading. Jupiter Neurosciences (JUNS) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesTrendsBuy This Stock JUNS vs. GALT, IMAB, ANIX, CLYM, IOBT, PLRX, PYXS, CPIX, EPIX, and IGMSShould you be buying Jupiter Neurosciences stock or one of its competitors? The main competitors of Jupiter Neurosciences include Galectin Therapeutics (GALT), I-Mab (IMAB), Anixa Biosciences (ANIX), Climb Bio (CLYM), IO Biotech (IOBT), Pliant Therapeutics (PLRX), Pyxis Oncology (PYXS), Cumberland Pharmaceuticals (CPIX), ESSA Pharma (EPIX), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical preparations" industry. Jupiter Neurosciences vs. Galectin Therapeutics I-Mab Anixa Biosciences Climb Bio IO Biotech Pliant Therapeutics Pyxis Oncology Cumberland Pharmaceuticals ESSA Pharma IGM Biosciences Galectin Therapeutics (NASDAQ:GALT) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, community ranking, institutional ownership and media sentiment. Which has preferable valuation and earnings, GALT or JUNS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectin TherapeuticsN/AN/A-$41.07M-$0.72-1.72Jupiter NeurosciencesN/AN/AN/AN/AN/A Does the MarketBeat Community favor GALT or JUNS? Galectin Therapeutics received 346 more outperform votes than Jupiter Neurosciences when rated by MarketBeat users. However, 100.00% of users gave Jupiter Neurosciences an outperform vote while only 58.91% of users gave Galectin Therapeutics an outperform vote. CompanyUnderperformOutperformGalectin TherapeuticsOutperform Votes34758.91% Underperform Votes24241.09% Jupiter NeurosciencesOutperform Votes1100.00% Underperform VotesNo Votes Do insiders & institutionals have more ownership in GALT or JUNS? 11.7% of Galectin Therapeutics shares are held by institutional investors. 50.1% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend GALT or JUNS? Galectin Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 787.10%. Given Galectin Therapeutics' higher probable upside, equities research analysts clearly believe Galectin Therapeutics is more favorable than Jupiter Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Jupiter Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Does the media favor GALT or JUNS? In the previous week, Jupiter Neurosciences had 1 more articles in the media than Galectin Therapeutics. MarketBeat recorded 2 mentions for Jupiter Neurosciences and 1 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 1.87 beat Jupiter Neurosciences' score of 0.94 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Galectin Therapeutics Very Positive Jupiter Neurosciences Positive Is GALT or JUNS more profitable? Company Net Margins Return on Equity Return on Assets Galectin TherapeuticsN/A N/A -163.15% Jupiter Neurosciences N/A N/A N/A SummaryGalectin Therapeutics and Jupiter Neurosciences tied by winning 5 of the 10 factors compared between the two stocks. Get Jupiter Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for JUNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JUNS vs. The Competition Export to ExcelMetricJupiter NeurosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.14M$6.53B$5.39B$8.47BDividend YieldN/A2.65%5.29%4.18%P/E RatioN/A8.7326.9919.79Price / SalesN/A257.90412.38137.71Price / CashN/A65.8538.2534.64Price / BookN/A6.466.844.53Net IncomeN/A$143.21M$3.22B$247.85M Jupiter Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JUNSJupiter NeurosciencesN/A$0.82+32.2%N/AN/A$27.14MN/A0.005Lockup ExpirationGap UpGALTGalectin Therapeutics1.2724 of 5 stars$1.28flat$11.00+759.4%-54.3%$81.01MN/A-1.759Gap DownIMABI-Mab2.5994 of 5 stars$0.99-5.7%$5.50+455.6%-32.8%$80.84M$3.27M0.00380News CoverageGap UpANIXAnixa Biosciences2.2132 of 5 stars$2.50-3.8%$9.00+260.0%+2.4%$80.49M$210,000.00-6.415News CoveragePositive NewsEarnings ReportUpcoming EarningsAnalyst ForecastCLYMClimb Bio2.8393 of 5 stars$1.18-1.7%$8.50+620.3%N/A$79.74MN/A-0.559IOBTIO Biotech2.69 of 5 stars$1.21+0.8%$9.33+671.3%-7.8%$79.72MN/A-0.8830Short Interest ↑PLRXPliant Therapeutics4.4074 of 5 stars$1.29-3.7%$13.31+932.0%-89.5%$79.19M$1.58M-0.3990PYXSPyxis Oncology1.8697 of 5 stars$1.23+2.5%$9.00+631.7%-67.9%$76.20M$16.15M-1.1960Gap DownCPIXCumberland Pharmaceuticals0.8298 of 5 stars$5.08-0.2%N/A+288.0%$76.00M$41.08M-6.6080Gap UpEPIXESSA Pharma2.1031 of 5 stars$1.69+1.8%$2.00+18.3%-73.2%$75.02MN/A-2.4550Positive NewsIGMSIGM Biosciences3.9761 of 5 stars$1.25+4.2%$5.50+340.0%-86.6%$74.72M$2.68M-0.34190 Related Companies and Tools Related Companies GALT Competitors IMAB Competitors ANIX Competitors CLYM Competitors IOBT Competitors PLRX Competitors PYXS Competitors CPIX Competitors EPIX Competitors IGMS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JUNS) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy JUNS Stock Free JUNS Stock Alerts